Theriva Biologics, Inc. (TOVX) Earnings History
Annual and quarterly earnings data from 1993 to 2025
Loading earnings history...
TOVX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TOVX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export TOVX earnings history in CSV or JSON format
Free sign-in required to download data
Theriva Biologics, Inc. (TOVX) Earnings Overview
As of May 8, 2026, Theriva Biologics, Inc. (TOVX) reported trailing twelve-month net income of -$23M, reflecting +89.1% year-over-year growth. The company earned $-0.56 per diluted share over the past four quarters.
Looking at the long-term picture, TOVX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2005.
Theriva Biologics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$164M net income, -297.1% margin), IMVT (-$464M net income), CRVS (-$44M net income), TOVX has comparable earnings metrics. Compare TOVX vs NKTR →
TOVX Earnings vs Peers
Earnings metrics vs comparable public companies
TOVX Historical Earnings Data (1993–2025)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$25M | +1.6% | -$15M | $-2.08 | - | - |
| 2024 | -$26M | -39.8% | -$26M | $-19.03 | - | - |
| 2023 | -$18M | +6.8% | -$21M | $-28.48 | - | - |
| 2022 | -$20M | -38.0% | -$22M | $-32.66 | - | - |
| 2021 | -$14M | -42.1% | -$14M | $-1.90 | - | - |
| 2020 | -$10M | +34.4% | -$10M | $-6.60 | - | - |
| 2019 | -$15M | -14.5% | -$16M | $-9.14 | - | - |
| 2018 | -$13M | +11.9% | -$18M | $-21.45 | - | - |
| 2017 | -$15M | +44.3% | -$26M | $-42.70 | - | - |
| 2016 | -$27M | +37.7% | -$39M | $-101.17 | - | - |
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TOVX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTOVX — Frequently Asked Questions
Quick answers to the most common questions about buying TOVX stock.
Is TOVX growing earnings?
TOVX EPS is $-0.56, with earnings growth accelerating to +89.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-23M.
What are TOVX's profit margins?
Theriva Biologics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are TOVX's earnings?
TOVX earnings data spans 1993-2025. The accelerating earnings trend is +89.1% YoY. Historical data enables comparison across business cycles.